Skip to main content
SpringerLink
Log in

Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. II. Clearance concepts applied to the evaluation of distribution kinetics

  • Published:
Journal of Pharmacokinetics and Biopharmaceutics Aims and scope Submit manuscript

Abstract

The disposition decomposition approach is employed to derive clearance parameters descriptive of drug distribution kinetics. The name distribution clearance, CL d ,is given to a characteristic constant of linear and some nonlinear pharmacokinetic systems. CL d is the clearance associated with the steady-state rate of drug transfer from the peripheral tissues to the systemic circulation. Also introduced is the elimination clearance, CL e ,which is associated with the total drug transfer rate from the systemic circulation in linear systems. Estimates of CL d and CL e are presented for several drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. P. Veng-Pedersen and W. R. Gillespie. The mean residence time in peripheral tissue. A linear disposition parameter useful for evaluating drug's tissue distribution.J. Pharmacokin. Biopharm. 12:535–543 (1984).

    Article  CAS  Google Scholar 

  2. P. Veng-Pedersen. Theorems and implications of a model independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. I. Derivations and theoretical analysis.J. Pharmacokin. Biopharm. 12:627–648 (1984).

    Article  CAS  Google Scholar 

  3. G. B. Park, R. P. Kershner, J. Angellotti, R. L. Williams, L. Z. Benet, and J. Edelson. Oral bioavailability and intravenous pharmacokinetics of amrinone in humans.J. Pharm. Sci. 72:817–819 (1983).

    Article  CAS  PubMed  Google Scholar 

  4. M. Rowland and S. Riegelman. Pharmacokinetics of acetylsalicylic acid and salicylic acid after intravenous administration in man.J. Pharm. Sci. 57:1313–1319 (1968).

    Article  CAS  Google Scholar 

  5. P. K. Narang, J. Adir, J. Josselson, A. Yacobi, and J. Sadler. Pharmacokinetics of bretylium in man after intravenous administration.J. Pharmacokin. Biopharm. 8:363–372 (1980).

    Article  CAS  Google Scholar 

  6. P. J. Pentikäinen, P. J. Neuvonen, M. Kekki, and A. Penttilä. Pharmacokinetics of intravenously administered bumetanide in man.J. Pharmacokin. Biopharm. 8:219–228 (1980).

    Article  Google Scholar 

  7. N. S. Aziz, J. G. Gambertoglio, E. T. Lin, H. Grausz, and L. Z. Benet. Pharmacokinetics of cefamandole using a HPLC assay.J. Pharmacokin. Biopharm. 6:153–164 (1978).

    Article  CAS  Google Scholar 

  8. A. Gerardin, J. B. Lecaillon, J. P. Schoeller, G. Humbert, and J. Guibert. Pharmacokinetics of cefroxadin (CGP9000) in man.J. Pharmacokin. Biopharm. 10:15–26 (1982).

    Article  CAS  Google Scholar 

  9. J. T. Burke, W. A. Wargin, R. J. Sherertz, K. L. Sanders, M. R. Blum, and F. A. Sarubbi. Pharmacokinetics of intravenous chloramphenical sodium succinate in adult patients with normal renal and hepatic function.J. Pharmacokin. Biopharm. 10:601–614 (1982).

    Article  CAS  Google Scholar 

  10. H. G. Boxenbaum, K. A. Geitner, M. L. Jack, W. R. Dixon, H. E. Spiegel, J. Symington, R. Christian, J. D. Moore, L. Weissman, and S. A. Kaplan. Pharmacokinetic and biopharmaceutic profile of chlordiazepoxide HCl in healthy subjects: Single-dose studies by the intravenous, intramuscular, and oral routes.J. Pharmacokin. Biopharm. 5:3–23 (1977).

    Article  CAS  Google Scholar 

  11. S. E. Tsuei, R. G. Moore, J. J. Ashley, and W. G. McBride. Disposition of synthetic glucocoricoids. I. Pharmacokinetics of dexamethasone in healthy adults.J. Pharmacokin. Biopharm. 7:249–264 (1979).

    Article  CAS  Google Scholar 

  12. S. A. Kaplan, M. L. Jack, K. Alexander, and R. E. Weinfeld. Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations.J. Pharm. Sci. 62:1789–1796 (1973).

    Article  CAS  PubMed  Google Scholar 

  13. A. W. Kelman and B. Whiting. Modeling of drug response in individual subjects.J. Pharmacokin. Biopharm. 8:115–130 (1980).

    Article  CAS  Google Scholar 

  14. J. R. Koup, D. J. Greenblatt, W. J. Jusko, T. W. Smith, and J. R., Koch-Weser. Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses.J. Pharmacokin. Biopharm. 3:181–192 (1975).

    Article  CAS  Google Scholar 

  15. P. G. Welling and W. A. Craig. Pharmacokinetics of intravenous erythromycin.J. Pharm. Sci. 67:1057–1059 (1978).

    Article  CAS  PubMed  Google Scholar 

  16. C. S. Lee, D. C. Brater, J. G. Gambertoglio, and L. Z. Benet. Disposition kinetics of ethambutol in man.J. Pharmacokin. Biopharm. 8:335–346 (1980).

    Article  CAS  Google Scholar 

  17. P. H. Hinderling, U. Gundert-Remy, D. Förster, and W. Gau. The pharmacokinetics of furazlocillin in healthy humans.J. Pharmacokin. Biopharm. 11:5–30 (1983).

    Article  CAS  Google Scholar 

  18. P. Chennavasin, R. A. Johnson, and D. C. Brater. Variability in derived parameters of furosemide pharmacokinetics.J. Pharmacokin. Biopharm. 9:623–633 (1981).

    Article  CAS  Google Scholar 

  19. M. Rowland, S. Riegelman, and W. L. Epstein. Absorption kinetics of griseofulvin in man.J. Pharm. Sci. 57:984–989 (1968).

    Article  CAS  PubMed  Google Scholar 

  20. R. Platzer, G. Reutemann, and R. L. Galeazzi. Pharmacokinetics of intravenous isosorbide dinitrate.J. Pharmacokin. Biopharm. 10:575–586 (1982).

    Article  CAS  Google Scholar 

  21. D. J. Greenblatt, R. I. Shader, K. Franke, D. S. MacLaughlin, J. S. Harmatz, M. D. Allen, A. Werner, and E. Woo. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazpam in humans.J. Pharm. Sci. 68:57–63 (1979).

    Article  CAS  PubMed  Google Scholar 

  22. D. J. Greenblatt, M. Divoll, J. S. Harmatz, and R. J. Shader. Pharmacokinetic comparison of sublingual lorazepam with intraveous, intramuscular, and oral lorazepam.J. Pharm. Sci. 71:248–252 (1982).

    Article  CAS  PubMed  Google Scholar 

  23. M. R. Dobrinska, W. Kukovetz, E. Beubler, H. Lorraine Leidy, H. J. Gomez, J. Demetriades, and J. A. Bolognese. Pharmacokinetics of the pivaloyloyethyl (POE) ester of rnethyldopa, a new prodrug of methyldopa.J. Pharmacokin Biopharm. 10:587–600 (1982).

    Article  CAS  Google Scholar 

  24. R. Jochemsen, J. J. H. Hogendoorn, J. Dingemanse, J. Hermans, J. K. Boeijinga, and D. D. Breimer. Pharmacokinetics and bioavailability of intravenous, oral, and rectal nitrazepam in humans.J. Pharmacokin. Biopharm. 10:231–245 (1982).

    Article  CAS  Google Scholar 

  25. J. W. Ward, A. McBurney, P. R. Farrow, and P. Sharp. Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.Eur. J. Clin. Pharmacol. 26:603–608 (1984).

    Article  CAS  PubMed  Google Scholar 

  26. C. V. Manion, D. Lalka, D. T. Baer, and M. B. Meyer. Absorption kinetics of procainamide in humans.J. Pharm. Sci. 66:981–984 (1977).

    Article  CAS  PubMed  Google Scholar 

  27. R. Gomeni, G. Bianchetti, R. Sega, and P. L. Morselli. Pharmacokinetics of propranolol in normal healthy volunteers.J. Pharmacokin. Biopharm. 5:183–192 (1977).

    Article  CAS  Google Scholar 

  28. T. W. Guentert, N. H. G. Holford, P. E. Coates, R. A. Upton, and S. Riegelman. Quinidine pharmacokinetics in man: Choice of a disposition model and absolute bioavailability studies.J. Pharmacokin. Biopharm. 7:315–330 (1979).

    Article  CAS  Google Scholar 

  29. A. Rakhit, N. H. G. Holford, T. W. Guentert, K. Maloney, and S. Riegelman. Pharmacokinetics of quinidine and three of its metabolites in man.J. Pharmacokin. Biopharm. 12:1–21 (1984).

    Article  CAS  Google Scholar 

  30. P. A. Meredith, A. W. Kelman, H. L. Elliott, and J. L. Reid. Pharmacokinetic and pharmacodynamic modelling of trimazosin and its major metabolite.J. Pharmacokin. Biopharm. 11:323–335 (1983).

    Article  CAS  Google Scholar 

  31. P. Veng-Pedersen. Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT.J. Pharmacokin. Biopharm. 5:513–531 (1977).

    Article  Google Scholar 

  32. P. Veng-Pedersen. Model independent steady state plasma level predictions in autonomie nonlinear pharmacokinetics I: Derivation and theoretical analysis.J. Pharm. Sci. 73:761–765 (1984).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Pharmacy, University of Iowa, 52242, Iowa City, IA

    William R. Gillespie & Peter Veng-Pedersen

Authors
  1. William R. Gillespie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Veng-Pedersen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gillespie, W.R., Veng-Pedersen, P. Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. II. Clearance concepts applied to the evaluation of distribution kinetics. Journal of Pharmacokinetics and Biopharmaceutics 13, 441–451 (1985). https://doi.org/10.1007/BF01061479

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01061479

Key words

Search

Navigation